Trials / Completed
CompletedNCT02984020
Korean Post-marketing Surveillance for Xeljanz
Korean Post-marketing Surveillance for Xeljanz(Registered) in Rheumatoid Arthritis and Psoriatic Arthritis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,041 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS.
Conditions
Timeline
- Start date
- 2016-05-13
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
- First posted
- 2016-12-06
- Last updated
- 2024-08-27
- Results posted
- 2024-08-27
Locations
49 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02984020. Inclusion in this directory is not an endorsement.